Abevmy 400 mg is a formulation of bevacizumab, a targeted cancer therapy classified as a monoclonal antibody. It is designed to interfere with the growth of blood vessels that supply oxygen and nutrients to tumors. By preventing the development of these blood vessels, it helps to limit tumor growth and spread. Abevmy is typically used in combination with chemotherapy for the treatment of several advanced or metastatic cancers. Its ability to specifically target a mechanism vital for tumor survival marks a significant step forward from traditional chemotherapy.

Mechanism of Action

Bevacizumab targets and blocks vascular endothelial growth factor, commonly known as VEGF. VEGF is a protein produced by both normal and cancerous cells, but tumors often overproduce it to stimulate the formation of new blood vessels. By binding directly to VEGF, bevacizumab prevents it from interacting with receptors on blood vessel walls. This inhibits the formation of new blood vessels, starving the tumor of its blood supply and thereby slowing its progression or making it more vulnerable to chemotherapy.

Uses

Abevmy is prescribed to manage several types of cancers, often in combination with other drugs. These include:

• Metastatic colorectal cancer

• Non-small cell lung cancer

• Advanced renal cell carcinoma

• Glioblastoma multiforme

• Cervical cancer

• Epithelial ovarian, fallopian tube, and primary peritoneal cancers

• Hepatocellular carcinoma (in combination with immunotherapy in select cases)

  Adverse Effects

  Common side effects

  • High blood pressure

  • Fatigue or weakness

  • Minor bleeding such as nosebleeds

  • Mouth ulcers

  • Headaches

  • Loss of appetite